Skip to content

Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation

Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04896346
Enrollment
5
Registered
2021-05-21
Start date
2022-02-09
Completion date
2023-06-30
Last updated
2022-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Scar, Scar

Keywords

stratagraft

Brief summary

The purpose of this study is to describe and better understand the scars of subjects that have been treated with Stratagraft tissue vs autograft.

Detailed description

This study will recruit patients who have previously been participants in the STRATA2016 study protocol. The patients will have comprehensive scar examinations conducted including the use of imaging, scar scale scores, pain and itch scales, scar volume measurements, and non-invasive skin measurements resulting in quantitative metrics of skin elasticity, stiffness, and color. Tissue biopsies will also be collected for histologic investigations into the scar. Each patient will have a biopsy taken of the autografted site, the Stratagraft site, and an area of normal, un-injured skin.

Interventions

OTHERPunch biopsy

punch biopsies will be used for histologic analysis and biochemical assays

OTHERnon-invasive photography, assessments, and measurements

photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity

Sponsors

Medstar Health Research Institute
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Participant in STRATA2016 clinical trial 2. ≥ 18 years of age

Exclusion criteria

1. Unable to provide informed consent 2. Known allergy to lidocaine 3. Scars are not appropriate for investigation based on clinical judgement by the Principal Investigator

Design outcomes

Primary

MeasureTime frameDescription
Characterize post-burn scar resulting from Stratagraft-treated and autograft-treated wounds1 DAYVancouver Scar Scale scores will be compared between scars originating from Stratagraft-treated burn wounds vs. autograft-treated burn wounds. The data will be normalized to uninjured skin. Min value for this scale is 0 and maximum value is 13. The higher the score, the worse the scar/outcome.

Secondary

MeasureTime frameDescription
Qualitatively characterize scar resulting from Stratagraft-treated and autograft-treated wounds1 DAYDigital images and 3D photography will be used to qualitatively characterize scars. Formalin-fixed, paraffin embedded (FFPE) samples will be used to generate sections which will be stained with Massons trichrome (overall collagen), Pircosirius red (type I and III collagen), Verhoeff Van Geison (elastin), and Fontana Masson (melanin) stains. These stained sections will be imaged and used to qualitatively characterize scar resulting from Stratagraft-treated burn wounds and SOC-treated burn wounds. Images will be normalized to uninjured skin.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026